Compare LXFR & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | CUVL |
|---|---|---|
| Founded | 1898 | 1999 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Miscellaneous |
| Sector | Industrials | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.6M | 374.2M |
| IPO Year | 2002 | 2004 |
| Metric | LXFR | CUVL |
|---|---|---|
| Price | $17.24 | $5.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $16.70 | N/A |
| AVG Volume (30 Days) | ★ 427.6K | 4.9K |
| Earning Date | 10-28-2026 | 08-27-2026 |
| Dividend Yield | ★ 3.02% | 0.58% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $384,600,000.00 | N/A |
| Revenue This Year | N/A | $0.47 |
| Revenue Next Year | $4.99 | $6.25 |
| P/E Ratio | $50.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.26 | $4.81 |
| 52 Week High | $19.45 | $8.20 |
| Indicator | LXFR | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 34.32 |
| Support Level | $17.19 | N/A |
| Resistance Level | $17.38 | $5.96 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 42.11 | 7.69 |
Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.